Yumanity Therapeutics Overview
- Founded
-
2014

- Status
-
Public
- Employees
-
41

- Stock Symbol
-
YMTX

- Investments
-
2
- Share Price
-
$1.74
- (As of Wednesday Closing)
Yumanity Therapeutics General Information
Description
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 40 Guest Street
- Suite 4410
- Boston, MA 02135
- United States
+1 (617) 000-0000
Yumanity Therapeutics Timeline
Yumanity Therapeutics Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.74 | $1.72 | $0.95 - $13.90 | $18.9M | 10.8M | 1.24M | -$4.24 |
Yumanity Therapeutics Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 7,433 | 14,223 | 171,611 | |
Revenue | 5,534 | 8,044 | 6,896 | 0 |
EBITDA | (41,750) | (36,980) | (54,789) | (29,473) |
Net Income | (44,202) | (39,503) | (57,487) | (31,209) |
Total Assets | 31,559 | 62,932 | 114,835 | 17,606 |
Total Debt | 10,866 | 27,689 | 35,289 | 15,220 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Yumanity Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Yumanity Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development
Drug Discovery
Boston, MA
41
As of 2021
00000
000000&0
00000
Yumanity Therapeutics Competitors (43)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
000000000 00000000 | Private Equity-Backed | San Diego, CA | 000 | 00000 | 0000000 0000 | 00000 |
0000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
0000 | Venture Capital-Backed | San Diego, CA | 00 | 00.000 | 0000000000 0 | |
000000000000 | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 00000000000 |
Yumanity Therapeutics Patents
Yumanity Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020245349-A1 | Compounds and uses thereof | Pending | 22-Mar-2019 | 0000000000 | |
CA-3134510-A1 | Compounds and uses thereof | Pending | 22-Mar-2019 | 0000000000 | |
CA-3127791-A1 | Compounds and uses thereof | Pending | 24-Jan-2019 | 0000000000 | |
EP-3914593-A1 | Compounds and uses thereof | Pending | 24-Jan-2019 | 0000000000 | |
AU-2020212034-A1 | Compounds and uses thereof | Pending | 24-Jan-2019 | C07D413/14 |
Yumanity Therapeutics Executive Team (13)
Yumanity Therapeutics Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
Cecil Pickett Ph.D | Yumanity Therapeutics | Board Member | 000 0000 |
David Arkowitz | Self | Board Member | 000 0000 |
Jeffery Kelly Ph.D | Self | Board Member | 000 0000 |
Kimberlee Drapkin | Self | Board Member | 000 0000 |
Lynne Zydowsky Ph.D | Yumanity Therapeutics | Board Member | 000 0000 |
Yumanity Therapeutics Signals
Yumanity Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Yumanity Therapeutics Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 | 06-Jun-2022 | 0000000 00 | Drug Discovery | 0000000 0 | |
Proteostasis Therapeutics | 22-Dec-2020 | Merger/Acquisition | Drug Discovery | 0000000 0 |